The U.S. FDA approved 22 drugs in June 2025, tying with March for the highest monthly total this year and contributing to 107 drugs approved in H1 2025. Notable approvals include Gilead’s twice-yearly long-acting HIV prevention injection and Nuvation Bio’s ROS1 inhibitor targeting non-small cell lung cancer. Arvinas and Pfizer filed for approval of the estrogen receptor PROTAC vepdegestrant. Monte Rosa Therapeutics will initiate a Phase 1 trial on a NEK7 degrader for inflammatory diseases. Novo Nordisk and Altimmune reported promising results for obesity and MASH treatments through GLP-1/glucagon dual receptor agonists and amylin analog combinations, signaling momentum in metabolism-related therapeutics.